NZ Neurology Research Review Issue 77 - MS Focus

In this issue:
  -  Cumulative effects of therapies on disability in RRMS
  -  Prediction of MS outcomes when switching to ocrelizumab
  -  Rapid and sustained B cell depletion with subcutaneous ofatumumab in relapsing MS
  -  MENACTRIMS practice guideline for COVID-19 vaccination in pwMS
  -  Humoral and T-cell responses to COVID-19 vaccine in pwMS treated with ocrelizumab
  -  Association of DMT and anti-CD20 infusion timing with humoral response to SARS-CoV-2 vaccines
  -  Depression in MS
  -  Treatment escalation vs immediate initiation of highly effective treatment for RRMS
  -  Safety and efficacy of the oral BTK inhibitor tolebrutinib in relapsing MS
  -  Epilepsy as a predictor of disease progression in MS

Please login below to download this issue (PDF)